Insider Selling: Insmed (NASDAQ:INSM) Insider Sells $100,012.80 in Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 640 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total transaction of $100,012.80. Following the completion of the transaction, the insider directly owned 56,397 shares in the company, valued at $8,813,159.19. The trade was a 1.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

• On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $183,401.01.
• On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $124,124.63.
• On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $241,968.68.

Insmed Trading Down 0.8%

Shares of INSM stock opened at $149.86 on Friday. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The company has a market capitalization of $31.96 billion, a PE ratio of -24.21 and a beta of 1.11. The firm has a 50 day moving average price of $174.90 and a two-hundred day moving average price of $159.93. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59.

Analysts Set New Price Targets

Several analysts recently issued reports on INSM shares. Cantor Fitzgerald boosted their price target on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Guggenheim dropped their target price on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Barclays started coverage on shares of Insmed in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price target on the stock. Wolfe Research set a $167.00 price target on shares of Insmed and gave the stock an “outperform” rating in a research report on Thursday, December 18th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $203.45.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after buying an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. raised its position in shares of Insmed by 5.8% in the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after buying an additional 1,112,824 shares in the last quarter. Capital International Investors lifted its holdings in shares of Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after acquiring an additional 74,994 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Finally, Duquesne Family Office LLC boosted its position in shares of Insmed by 3.0% during the 3rd quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock worth $348,999,000 after acquiring an additional 70,000 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.